Gadovist Stungulyf, lausn 1,0 mmól/ml আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

gadovist stungulyf, lausn 1,0 mmól/ml

bayer ab - gadobutrolum inn - stungulyf, lausn - 1,0 mmól/ml

Gadovist Stungulyf, lausn í áfylltri sprautu 1,0 mmól/ml আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

gadovist stungulyf, lausn í áfylltri sprautu 1,0 mmól/ml

bayer ab - gadobutrolum inn - stungulyf, lausn í áfylltri sprautu - 1,0 mmól/ml

Valpress Comp Filmuhúðuð tafla 160/12,5 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 160/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg

Valpress Comp Filmuhúðuð tafla 80/12,5 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

valpress comp filmuhúðuð tafla 80/12,5 mg

teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg

Candpress Comp Tafla 16 mg/12,5 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

candpress comp tafla 16 mg/12,5 mg

teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg

Riltrava Aerosphere ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Kairasec Tafla 8 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 8 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg

Kairasec Tafla 16 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 16 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg

Kairasec Tafla 32 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 32 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg

Teriparatide Sun ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatíð - osteoporosis; osteoporosis, postmenopausal - kalsíumsterastasis - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.